Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
Sana Biotechnology (NASDAQ: SANA) has appointed Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. Dr. Patel brings extensive experience in drug development and clinical research, having contributed to the advancement of 10 FDA-approved treatments. His expertise in immunology and autoimmune diseases aligns with Sana's focus on engineered cells and its clinical pipeline, particularly for B-cell mediated autoimmune diseases and type 1 diabetes.
Previously, Dr. Patel served as EVP and CSO at UCB, where he played a key role in pipeline transformation. He also spent 10 years at Novartis, leading research in autoimmune, transplantation, and inflammation disease areas. Sana currently has four ongoing clinical trials across seven indications, positioning the company to advance its mission of developing innovative therapies for patients in need.
Sana Biotechnology (NASDAQ: SANA) ha nominato Dhaval Patel, M.D., Ph.D. come Vice Presidente Esecutivo e Direttore Scientifico. Il Dr. Patel porta con sé un'ampia esperienza nello sviluppo di farmaci e nella ricerca clinica, avendo contribuito all'avanzamento di 10 trattamenti approvati dalla FDA. La sua esperienza in immunologia e malattie autoimmuni si allinea con l'orientamento di Sana verso cellule ingegnerizzate e il suo pipeline clinico, in particolare per malattie autoimmuni mediate da cellule B e diabete di tipo 1.
In precedenza, il Dr. Patel ha ricoperto il ruolo di EVP e CSO presso UCB, dove ha svolto un ruolo chiave nella trasformazione del pipeline. Ha inoltre trascorso 10 anni in Novartis, guidando la ricerca nelle aree di malattie autoimmuni, trapianti e infiammazione. Attualmente, Sana ha quattro studi clinici in corso su sette indicazioni, posizionando l'azienda per avanzare la sua missione di sviluppare terapie innovative per i pazienti bisognosi.
Sana Biotechnology (NASDAQ: SANA) ha nombrado a Dhaval Patel, M.D., Ph.D. como Vicepresidente Ejecutivo y Director Científico. El Dr. Patel aporta una amplia experiencia en desarrollo de medicamentos e investigación clínica, habiendo contribuido al avance de 10 tratamientos aprobados por la FDA. Su experiencia en inmunología y enfermedades autoinmunes se alinea con el enfoque de Sana en células diseñadas y su pipeline clínico, especialmente para enfermedades autoinmunes mediadas por células B y diabetes tipo 1.
Anteriormente, el Dr. Patel se desempeñó como EVP y CSO en UCB, donde jugó un papel clave en la transformación del pipeline. También pasó 10 años en Novartis, liderando la investigación en áreas de enfermedades autoinmunes, trasplantes e inflamación. Actualmente, Sana tiene cuatro ensayos clínicos en curso en siete indicaciones, posicionando a la empresa para avanzar en su misión de desarrollar terapias innovadoras para pacientes necesitados.
사나 생명공학 (NASDAQ: SANA)는 다발 파텔, M.D., Ph.D.를 임원 부사장 및 최고 과학 책임자로 임명했습니다. 파텔 박사는 약물 개발 및 임상 연구에 대한 광범위한 경험을 가지고 있으며, FDA 승인을 받은 10개 치료법의 발전에 기여했습니다. 그의 면역학 및 자가면역 질환에 대한 전문성은 사나의 엔지니어링 세포와 임상 파이프라인, 특히 B세포 매개 자가면역 질환 및 제1형 당뇨병에 대한 초점과 잘 맞습니다.
이전에 파텔 박사는 UCB에서 EVP 및 CSO로 재직하며 파이프라인 변환에 중요한 역할을 했습니다. 그는 또한 노바티스에서 10년을 보내며 자가면역 질환, 이식 및 염증 질환 영역의 연구를 이끌었습니다. 현재 사나는 7개 적응증에 걸쳐 4개의 임상 시험을 진행 중이며, 이는 환자들이 필요로 하는 혁신적인 치료법을 개발하려는 회사의 임무를 추진하는 데 도움이 됩니다.
Sana Biotechnology (NASDAQ: SANA) a nommé Dhaval Patel, M.D., Ph.D. au poste de Vice-Président Exécutif et Directeur Scientifique. Le Dr Patel apporte une vaste expérience en développement de médicaments et en recherche clinique, ayant contribué à l'avancement de 10 traitements approuvés par la FDA. Son expertise en immunologie et en maladies auto-immunes s'inscrit dans l'axe de Sana sur les cellules ingénierées et son pipeline clinique, en particulier pour les maladies auto-immunes médiées par les cellules B et le diabète de type 1.
Auparavant, le Dr Patel a été EVP et CSO chez UCB, où il a joué un rôle clé dans la transformation du pipeline. Il a également passé 10 ans chez Novartis, dirigeant la recherche dans les domaines des maladies auto-immunes, de la transplantation et de l'inflammation. Actuellement, Sana dispose de quatre essais cliniques en cours sur sept indications, positionnant l'entreprise pour faire avancer sa mission de développement de thérapies innovantes pour les patients dans le besoin.
Sana Biotechnology (NASDAQ: SANA) hat Dhaval Patel, M.D., Ph.D. zum Executive Vice President und Chief Scientific Officer ernannt. Dr. Patel bringt umfangreiche Erfahrung in der Arzneimittelentwicklung und klinischen Forschung mit, da er zur Weiterentwicklung von 10 von der FDA zugelassenen Behandlungen beigetragen hat. Seine Expertise in Immunologie und Autoimmunerkrankungen passt zu Sanas Fokus auf ingenieerte Zellen und seiner klinischen Pipeline, insbesondere für B-Zell vermittelte Autoimmunerkrankungen und Typ-1-Diabetes.
Zuvor war Dr. Patel EVP und CSO bei UCB, wo er eine Schlüsselrolle bei der Transformation der Pipeline spielte. Er verbrachte auch 10 Jahre bei Novartis und leitete die Forschung in den Bereichen Autoimmunerkrankungen, Transplantation und Entzündung. Sana hat derzeit vier laufende klinische Studien in sieben Indikationen, wodurch das Unternehmen in der Lage ist, seine Mission voranzutreiben, innovative Therapien für bedürftige Patienten zu entwickeln.
- Appointment of highly experienced CSO with contributions to 10 FDA-approved treatments
- Alignment of new CSO's expertise with Sana's focus on engineered cells and autoimmune diseases
- Four ongoing clinical trials across seven indications, indicating active pipeline development
- None.
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.
“We are thrilled to welcome Dhaval to Sana’s senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future,” said Steve Harr, Sana’s President and Chief Executive Officer. “Through decades of experience in research, drug discovery, drug development, and clinical care, Dhaval has successfully led programs in research and early development with substantial contributions to the advancement of 10 FDA-approved treatments. His expertise in immunology and autoimmune diseases make him ideally suited to help advance our clinical pipeline, particularly for B-cell mediated autoimmune diseases and type 1 diabetes, and accelerate our innovation.”
Dr. Patel was previously Executive Vice President and Chief Scientific Officer at UCB, where he played a key role in its recent pipeline transformation. He and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®), and zilucoplan (Zilbrysq®). Prior to UCB, Dr. Patel spent 10 years at Novartis, most recently as the Head of Research of the Novartis Institutes for BioMedical Research (NIBR) Europe. During his tenure, he led research in autoimmune, transplantation, and inflammation disease areas contributing to the registration of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) in multiple indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Prior to joining industry, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. He also spent nine years at the Duke University School of Medicine, culminating in his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and is board certified in internal medicine, rheumatology, and allergy & immunology.
Dr. Patel added, “I am delighted to join Sana at this exciting time of growth. Our hypoimmune platform provides a unique opportunity to push the boundaries of science and transform the future for patients. With four ongoing clinical trials across seven indications, including in B-cell mediated autoimmune diseases, type 1 diabetes, and blood cancers, we are poised to take a significant step forward in the company’s mission to bring innovative, life-changing therapies to patients in need. I am eager to collaborate with this talented team to accelerate our journey towards groundbreaking advancements and real-world impact.”
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, Bothell, WA and Rochester, NY. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-Q dated August 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
Who is Sana Biotechnology's new Chief Scientific Officer?
What is Dr. Dhaval Patel's background before joining Sana Biotechnology (SANA)?
How many clinical trials does Sana Biotechnology (SANA) currently have ongoing?
What are the main areas of focus for Sana Biotechnology (SANA)?
